CSIMarket
 
Bluebird Bio Inc   (BLUE)
Other Ticker:  
 
 
Price: $1.0200 $0.12 13.447%
Day's High: $1.04 Week Perf: 7.12 %
Day's Low: $ 0.90 30 Day Perf: 3.7 %
Volume (M): 10,515 52 Wk High: $ 5.53
Volume (M$): $ 10,725 52 Wk Avg: $2.27
Open: $0.91 52 Wk Low: $0.85



 Market Capitalization (Millions $) 111
 Shares Outstanding (Millions) 109
 Employees -
 Revenues (TTM) (Millions $) 22
 Net Income (TTM) (Millions $) -91
 Cash Flow (TTM) (Millions $) 12
 Capital Exp. (TTM) (Millions $) 17

Bluebird Bio Inc
Bluebird Bio Inc. is a biotechnology company that develops gene therapies for severe genetic diseases and cancer. The company is known for its focus on using gene therapy to treat inherited blood disorders, such as beta-thalassemia and sickle cell disease. Bluebird Bio also develops CAR-T cell therapies for various types of cancer. The company's gene therapies involve modifying a patient's own cells to correct or replace the faulty gene responsible for the disease. Bluebird Bio aims to provide long-lasting and potentially curative treatment options for patients suffering from these devastating conditions.


   Company Address: 455 Grand Union Boulevard Somerville 2145 MA
   Company Phone Number: 499-9300   Stock Exchange / Ticker: NASDAQ BLUE
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Business Update

bluebird bio, Inc. (Nasdaq: BLUE), a pioneering gene therapy company, has ann...

Published Wed, May 29 2024 11:38 AM UTC

'bluebird bio Strengthens Leadership Team with Appointment of O. James Sterling as Chief Financial Officer'bluebird bio, Inc. (Nasdaq: BLUE), a pioneering gene therapy company, has announced the appointment of O. James Sterling as its Chief Financial Officer (CFO), effective June 10, 2024. This strategic move underscores the company's commitment to bolstering its financial l...

Business Update

Bluebird Bio Faces Class Action Lawsuit: Investors Alerted of Impending Deadline

Published Mon, May 20 2024 4:30 AM UTC

The renowned law firm of Kirby McInerney LLP has recently reminded investors of the looming May 28, 2024 deadline to assume the role of lead plaintiff in a federal securities class action. This legal action has been initiated on behalf of individuals who acquired securities of bluebird bio, Inc. (Blue or the Company) (NASDAQ: BLUE) during the period from April 24, 2023, to D...

Business Update

'Investor Alert: Kirby McInerney LLP Urges Bluebird Bio, Inc. Shareholders to Act Before May 2024 Deadline in Class Action Lawsuit Amidst Company's Revenue Surge and Subsequent Stock Plunge'

Published Sat, May 18 2024 12:15 AM UTC

Blue Investor Alert: Kirby McInerney LLP Notifies Bluebird Bio, Inc. Investors of Upcoming Lead Plaintiff Deadline in Class Action Lawsuit'New York, NY ??' Kirby McInerney LLP, a law firm renowned for its expertise in securities litigation, has announced a significant development that could impact investors of Bluebird Bio, Inc. (NASDAQ: BLUE). The firm has issued a reminde...

Business Update

Bluebird Bio Faces Lawsuit and Compliance Woes Over Failure to File Annual Report, Investors Urged to Take Action

Published Fri, May 17 2024 10:15 PM UTC

Bluebird Bio Faces Lawsuit Over Failure to Comply with Nasdaq Listing RuleOn May 28, 2024, the law firm of Kirby McInerney LLP announced the upcoming deadline for investors to seek the role of lead plaintiff in a federal securities class action against bluebird bio, Inc. The lawsuit was filed on behalf of those who acquired Blue's securities between April 24, 2023, and Decem...

Business Update

Unprecedented Revenue Surge in Q1 2024 for Bluebird Bio Inc. Bolsters Gene Therapy Progress.

Published Thu, May 9 2024 11:47 AM UTC

CSIMarket.com is pleased to delve into the recent progress and achievements of Bluebird Bio, Inc. (NASDAQ: BLUE) (Bluebird), a notable company advancing the frontiers of commercial gene therapy. Bluebird has recently announced its exceptional first-quarter results for 2024, and we will take a close look at this outstanding performance.The financial report released by Bluebi...






 

Bluebird Bio Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com